RenaudBonnet

Practice Leader Private Equity

Paris + 33.1.56.59.39.14

Contact

Partager

Renaud Bonnet intervient dans les domaines du private equity, des fusions-acquisitions et du droit boursier. Il co-dirige la pratique Private Equity de Jones Day dans le monde.

Il accompagne principalement des entreprises de croissance (cotées ou non) et leurs actionnaires dirigeants, industriels ou financiers, notamment dans les secteurs du logiciel, de l'internet et des biotech/medtech, tout au long de leur développement depuis leur création jusqu'à leur adossement industriel ou leur introduction en bourse et, au-delà, dans leur vie de sociétés cotées. A ce titre, il conduit chaque année un grand nombre d'opérations de capital-risque, LBO, fusions-acquisitions et boursières (IPOs, placements privés, OPAs,...).

Les entreprises récemment représentées par Renaud Bonnet comptent notamment Adocia, Ansys, Cellectis, Criteo, Deezer, Devialet, EcoVadis, HRA Pharma, Ivalua, 360Learning, ManoMano, Nanobiotix, Planisware, Prodways, Sigfox, Talend et Voltalia, et les investisseurs stratégiques ou financiers, Abingworth, Alven, Bain Capital Ventures, Bpifrance, Creadev, Danone Ventures, Elaia, Eurazeo, Goldman Sachs, Hi Inov, Idinvest, Institut Pasteur, Medicxi Ventures, Orange, Sanofi, Seventure, Temasek et Sofinnova.

Parmi les transactions représentatives de son expérience figurent : plus de 40 introductions en bourse en France et celles de Criteo, Cellectis, Nanobiotix et Talend sur le Nasdaq ; les OPAs de Completel, Wavecom, Assystem et TxCell ; les LBO d’HRA Pharma par Astorg et Goldman Sachs, d’Orolia par Eurazeo, d'A2Mac1 par Five Arrows et de Brico Privé pat Florac ; les cessions de Novexel à AstraZeneca et de Synthesio à IPSOS ; l'acquisition de sociétés de technologie françaises par Autodesk, Criteo, SAP et Ansys ; et les derniers tours de financement de Devialet, ManoMano, Ivalua ou encore EcoVadis.

Renaud Bonnet a été membre de la commission consultative “Opérations et information financières des émetteurs” de l'AMF de 2017 à 2019.

Expérience

  • 360Learning raises $200 million in financing roundJones Day advised 360Learning, a French-based company having developed a collaborative learning SaaS platform to help companies unlock learning based on collective expertise, in connection with its $200 million round of financing led by Sumeru, Silver Lake, and Softbank.
  • EcoVadis raises $200 million in Series B roundJones Day assisted EcoVadis SAS, a provider of environmental, social, and ethical performance ratings for global supply chains, in connection with their $200 million Series B round of financing led by CVC Growth Partners.
  • Bpifrance and Eurazeo participate in $500 million Series E financing round of ContentsquareJones Day represented Bpifrance and Eurazeo in connection with the $500 million Series E round of financing of Contentsquare, the global leader in digital experience analytics, led by SoftBank Vision Fund 2.
  • Nanobiotix completes $113.3 million IPO on NasdaqJones Day represented Nanobiotix S.A., a French clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, in connection with its $113.3 million initial public offering in the United States and listing on Nasdaq.
  • AccorHotels acquires AvailproJones Day advised AccorHotels, a French multinational hotel group, in connection with its acquisition of Availpro, a leading European software provider to hoteliers.
  • HDL Development makes $500 million take-over bid for AssystemJones Day advised HDL Development, a holding company majority owned by Assystem's founding president, in its $500 million take-over bid for Assystem, including the bank financing and guarantee in connection with the bid.
  • BNP Paribas invests in Fortia Financial SolutionsJones Day represented BNP Paribas Securities Services in connection with its investment in Fortia Financial Solutions, a developer and marketer of financial compliance and risk monitoring solutions.
  • Institut Pasteur participates in €50 million financing round of Argobio StudioJones Day advised Institut Pasteur in the participation in €50 million round of financing of Argobio Studio, a French company developing projects in biotechnology.
  • ManoMano completes $355 million Series F financing roundJones Day represented ManoMano, an online marketplace specializing in the sale of DIY, home improvement, and gardening products, in connection with its $355 million Series F round of financing led by Dragoneer Investment Group with the participation of existing investors Temasek, General Atlantic, Eurazeo, Bpifrance, Aglaé Ventures, Kismet Holdings, and Armat Group.
  • Cellectis completes $228 million IPOJones Day represented Cellectis SA, a French biotechnology company that develops novel cancer treatments, in connection with its $228 million initial public offering in the United States and Nasdaq listing.
  • Devialet raises €100 million in funding from group of investorsJones Day represented Devialet SA, a market leader in high end amplifiers, in connection with the €100 million (US$106 million) funding from a group of investors including Ginko Ventures, Foxconn Interconnect Technology, Groupe Renault, Sharp Corporation, Playground Global, Naver, Korelya, Roc Nation, Future French Champions, CM-CIC Investissement, and Bpifrance.
  • Trace One sold to HgCapitalJones Day advised Trace One SA, a leading Software as a Service (“SaaS”) platform for the retail and private label goods sectors, in connection with its sale to HgCapital.
  • Orolia sold to EurazeoJones Day advised Orolia S.A., a world leader in reliable GPS-type signals, and its main historical shareholder Mr. Laurent Asscher, in connection with Orolia's leveraged buyout with Eurazeo PME.
  • Criteo completes IPO of American Depository Shares on NASDAQJones Day advised Criteo S.A., a France-based technology company specializing in performance display advertising, in connection with its issuance of $288 million of Ordinary Shares in an initial public offering in the form of American Depository Shares on NASDAQ.
  • Laboratoire HRA-Pharma sold to Astorg Partners and Goldman SachsJones Day advised Laboratoire HRA-Pharma SAS, a French pharmaceutical company, and its management in connection with its leveraged buy-out by Astorg Partners and Goldman Sachs.
  • Talend completes IPO of American Depositary Shares on NASDAQJones Day represented Talend SA, a software vendor specializing in big data and cloud integration solutions, in connection with its issuance of $94.5 million of American Depositary Shares in an initial public offering on NASDAQ.
  • Creadev and Temasek lead €140 million Series C financing of InnovaFeedJones Day represented Creadev and Temasek in connection with their participation in a €140 million Series C financing of InnovaFeed, a leader in the rearing of insects for animal feed, on the equity portion representing half of the fundraising value.
  • Voltalia completes €170 million share capital increaseJones Day represented Voltalia, an international renewable energy producer, in connection with its €170 million (US$188.6 million) share capital increase through a free allotment of warrants to its shareholders and an international offering to institutional investors inside and outside of France.
  • OVHcloud acquires EXTEN Technologies, Inc.Jones Day advised OVHcloud, a global cloud leader and the largest European cloud provider, in its acquisition of technology and certain assets of EXTEN Technologies, Inc., a U.S.-based storage software company specializing in NVMe over Fabrics.
  • Goldman Sachs invests in NuxeoJones Day represented Goldman Sachs International in connection with its primary and secondary investment in Nuxeo S.A., a developer of a leading enterprise content management platform which enables organizations to manage complex digital content at massive scale.
    •

    March 2023 White Paper

    2022 Annual M&A/PE Review and 2023 Forecast

    December 2022 Webinars

    Webinar Series: Cross-Practice Issues in the Life Sciences

    January 2022 White Paper

    2021 Transactional Year in Review and 2022 Forecast

    January 2022 White Paper

    FDI Regimes Continue to Expand and Increase Scrutiny of Transactions Worldwide

    February 2021 White Paper

    2020 Transactions Year in Review

    August 2019 VIDÉOS

    Jones Day – le bureau de Paris – Sciences de la vie

    June 2016 Alert

    Brexit: United Kingdom Votes to Leave the EU

    September 18-20, 2023 Speaking Engagements

    Jones Day lawyers to attend IPEM 2023

    December 2022 Webinars

    Webinar Series: Cross-Practice Issues in the Life Sciences

    • 29 janvier 2014
      Le private equity en 2014 : tendances et opportunités
    • 29 janvier 2013
      Le Private Equity : où en sommes-nous ?
    • 20 septembre 2012
      Le financement des PME: actualités juridiques et tendances de marché - en partenariat avec NYSE Euronext et Société Générale
    • September 20, 2012
      SME Financing: legal news and market trends – in collaboration with NYSE Euronext and Société Générale
    • 5 avril 2011
      Atelier « Fusions & Acquisitions » de France Biotech - Le point de vue de l'avocat, intervention de Renaud Bonnet
    • 17 juin 2009
      Introductions en bourse : la mission de l’avocat conseil et la problématique règlementaire, Conférence “Penser à votre introduction en bourse : osé ... mais peut-être astucieux ! ” organisée par la Société Générale
    • 3 avril 2007
      Introductions en bourse : feuille de route pratique
    • 18 mai 2006
      Petit déjeuner thématique "Stock options, BCE, actions gratuites"
    • 14 mars 2006
      Cours à l'ESSEC, "Mécanisme d'incitation des managers"

    Avant d’envoyer cet e-mail, veuillez prendre note de ce qui suit :

    Les informations contenues sur le site www.jonesday.com sont destinées à un usage général et ne constituent pas des conseils juridiques. L’envoi et la réception de cet e-mail n’ont pas pour effet de créer une relation avocat-client. Aucun envoi de votre part à un membre du Cabinet ne sera traité comme confidentiel ou protégé à moins que nous n’ayons donné notre accord pour vous représenter. En envoyant cet e-mail, vous confirmez avoir lu et compris la présente notification.